Advertisement

Cisplatin Nephrotoxicity: New Insights Into Mechanism

  • R. Safirstein
  • A. Z. Zelent
  • R. Gordon
Part of the Developments in Oncology book series (DION, volume 53)

Abstract

Cis-dichlorodiammine platinum (II), or cisplatin, has emerged as a principal chemotherapeutic agent in the treatment of otherwise resistant solid tumors and is currently among the most widely used agents in the chemotherapy of cancer. The chief limit to its greater efficacy, however, is its nephrotoxicity, which has made it necessary both to lower its dosage and actively hydrate patients to reduce it. These techniques have proven to be only partially successful as renal failure occurs even at such low doses and especially after its repeated administration (1,2). Use of other means to protect the kidney (3–5) are only partially successful and of uncertain clinical application. It may not be possible to alter or prevent the renal toxicity of cisplatin, however, until a more basic understanding of that toxicity is obtained. This paper summarizes what is known about the biochemical and physiologic aspects of cisplatin nephrotoxicity and gives the results of some recent experiments into its possible mechanism.

Keywords

Outer Medulla Outer Cortex Outer Stripe Renal Fluid Electrolyte Pyrazinoic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Meijer S, Mulder NH, Sleijfer DT, et al. Pharmacol. 8:27–30, 1982.Google Scholar
  2. 2.
    Goldstein MH, Safirstein R. Abstracts, 8th International Congress of Nephrology, June 1981, p.229.Google Scholar
  3. 3.
    Yuhas JM, Culo F. Cancer Treat Rep 64: 57–64, 1980.PubMedGoogle Scholar
  4. 4.
    Borch RF, Pleasants ME., Proc. Natl. Acad. Sci USA 76:6611–6614, 1979.PubMedCrossRefGoogle Scholar
  5. 5.
    Berry J-P, Pauwells C, Tlouzeau S, Lespinats G. Cancer Research 44: 2864–2868, 1984.PubMedGoogle Scholar
  6. 6.
    Litterst CL, Torres IJ, Guarino AM. J. Clin. Hemat. and Oncol.7:169–178, 1977.Google Scholar
  7. 7.
    Safirstein R, Daye M, Miller P, Guttenplan J. Fed. Proc. 40:651A, 1980.Google Scholar
  8. 8.
    Safirstein R, Miller P, Guttenplan JB. Kidney Int. 25: 753–758, 1984.PubMedCrossRefGoogle Scholar
  9. 9.
    Jacobs C, Kalman SM, Tretton M, Weiner MW. Cancer Treat. Rep. 64: 1223–1226, 1980.PubMedGoogle Scholar
  10. 10.
    Levi J, Jacobs C, Kalman S, Migue M, Weiner MW., J. Pharmacol. Exp. Ther 213:545–550, 1980.PubMedGoogle Scholar
  11. 11.
    Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J. Int. J. Androl 10:325–245, 1987.PubMedCrossRefGoogle Scholar
  12. 12.
    Safirstein RL, Daye M, Guttenplan JB. Cancer Letters 18:329–338, 1983.PubMedCrossRefGoogle Scholar
  13. 13.
    Lecointe P, Mauet J-P, Butone J-L. Biochem. Biophys. Res. Comm. 90: 209–213, 1979.PubMedCrossRefGoogle Scholar
  14. 14.
    Safirstein R, Miller P, Dikman S, Lyman N, Shapiro C. Am. J. Physiol: 241 (Renal Fluid Electrolyte Physiol. 10): F175–F185, 1982.Google Scholar
  15. 15.
    Winston J, Safirstein R. Amer. J. Physiol. 249 (Renal Fluid Electrolyte Physiol.18): F490–F496, 1985.PubMedGoogle Scholar
  16. 16.
    Clifton G, Pearce C, O’Neill W, Shah S, Wallin J. Clin Res. 28: 655A, 1980.Google Scholar
  17. 17.
    Safirstein R, Miller P, Dikman S. In:Acute Renal Failure, Eliahou HE ed., Libbey, London, pp 91–95, 1982.Google Scholar
  18. 18.
    Humes HD, Weinberg JM. In: Acute Renal Failure, eds Brenner BM, Lazarus JM, Phila., Saunders WB, 1983, pp 47–98.Google Scholar
  19. 19.
    Harder HC, Rosenberg B. Int. J. Cancer 6:207–216, 1970.PubMedCrossRefGoogle Scholar
  20. 20.
    Howie JA, Gale GR. Biochem. Pharmacol. 19; 2757–2762, 1970.CrossRefGoogle Scholar
  21. 21.
    Munchausen LL, Rahn RO. Cancer Chemother. Rep. 59:643–646, 1975.PubMedGoogle Scholar
  22. 22.
    Roberts JJ, Prascoe JM Nature 235:282–284, 1972.PubMedCrossRefGoogle Scholar
  23. 23.
    Zwelling LA, Anderson T, Kohn KW. Cancer Res. 39:365–369, 1979.PubMedGoogle Scholar
  24. 24.
    Harder HC, Smith RG, LeRoy A Proc. Amer Assoc Cancer Research 17:80, 1976.Google Scholar
  25. 25.
    Plooy ACM, van Dijk M, Lohman PH. Cancer Research 44: 2043–2051, 1984.PubMedGoogle Scholar
  26. 26.
    Munro HN, Fleck A. Methods in Biochemical Analysis. Ed. D. Gloick, New York, John Wiley and Sons 1966, V14, pp.113–176.CrossRefGoogle Scholar
  27. 27.
    Ceriotti G. J. Biol. Chem. 198: 297–303, 1952.PubMedGoogle Scholar
  28. 28.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. J. Biol. Chem. 193: 265–268, 1951.PubMedGoogle Scholar
  29. 29.
    Fraval HNA, Rawlings CJ, Roberts JJ, Mutat. Res. 51:121–132, 1978.PubMedCrossRefGoogle Scholar
  30. 30.
    Threlfall G, Taylor DM, Buck AT. Lab Invest. 15: 1477–1485, 1966.PubMedGoogle Scholar
  31. 31.
    Laurent G, Maldague P, Carlier M, Tulkens PM. Antimicrob Agents Chemother 24: 586–593, 1983.PubMedGoogle Scholar
  32. 32.
    Toback FG. Control of renal regeneration after acute tubule necrosis. In Nephrology. Robinson RR ed., Springer-Verlag, New York, Berlin, Heidelberg, Tokyo, 1984, pp 748–762.CrossRefGoogle Scholar
  33. 33.
    Oliver J. Am J Med 15: 535–559, 1953.PubMedCrossRefGoogle Scholar
  34. 34.
    Haagsma BH, Pound AW. Br. J. Exp Pathol 61:229–241, 1980.PubMedGoogle Scholar
  35. 35.
    Tsivitse P, Abboud HE, Saunders C, Krauss TC. Kidney Int. 31: 184A, 1987.Google Scholar
  36. 36.
    Stanton RC, Seifter JL. IBID 182A.Google Scholar
  37. 37.
    Boyer DC, Stanton RC, Seifter JL. IBID 161A.Google Scholar
  38. 38.
    Cowley BD Jr, Smardo FL Jr, Grantham JJ, Calvert JP. Kidney.Google Scholar
  39. 39.
    Ellis RW, Deo D, Shih TY, Gonda MA, Young HA, Tsuchida N, Lowy DR, Scolnick EM. Nature 292: 506–511, 1981.PubMedCrossRefGoogle Scholar
  40. 40.
    Curran T, Peters G, von Beveren C, Teich NM, Verma IM. J. Virol. 44: 674–682, 1982.PubMedGoogle Scholar
  41. 41.
    Muller R, Slamon DJ, Tremblay JN, Cline MJ, Verma IM. Nature.Google Scholar
  42. 42.
    Bishop JM. Ann. Rev. Biochem 52: 301–354, 1983.PubMedCrossRefGoogle Scholar
  43. 43.
    Goyette M, Petropoulos CJ, Shank PR, Fausto N. Science 219: 510–512, 1983.PubMedCrossRefGoogle Scholar
  44. Goyette M, Petropoulos CJ, Shank PR, Fausto N. Int.31:163A, 1987.Google Scholar
  45. 44.
    Marx JL. Science 224: 271–274, 1984.PubMedCrossRefGoogle Scholar
  46. 45.
    Exton JH. J. Clin. Invest. 75: 1753–1757, 1985.PubMedCrossRefGoogle Scholar
  47. 46.
    Berridge MJ. Biochem J. 220: 345–360, 1984.PubMedGoogle Scholar
  48. 47.
    Berk BC, Brock TA, Webb RC, Taubman MB, Atkinson WJ, Gimbrone MA, Jr., Alexander RW. J. Clin. Invest. 75: 1083–1086, 1985.PubMedCrossRefGoogle Scholar
  49. 48.
    Mene P, Abboud HE, Dubyak GR, Dorleto P, Scarpa A, Dunn MJ.Kidney Int. 31: 175A, 1987.Google Scholar
  50. 49.
    Abboud HE, Dorleto P, Shultz P, Poptic E, Silver B. Kidney Int. 31: 158A, 1987.Google Scholar
  51. 50.
    Schor N, Ichikawa I, Brenner BM. Kidney Int. 20: 442–451, 1981.PubMedCrossRefGoogle Scholar
  52. 51.
    Baylis C, Rennke HR, Brenner BM. Kidney Int. 12: 344–353, 1977.PubMedCrossRefGoogle Scholar
  53. 52.
    Blantz RC. J. Clin. Invest 55: 621–635, 1975.PubMedCrossRefGoogle Scholar
  54. Blantz RC. J. Clin. Invest 299: 640–644, 1982.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1988

Authors and Affiliations

  • R. Safirstein
  • A. Z. Zelent
  • R. Gordon

There are no affiliations available

Personalised recommendations